

- resistance is a function of long elimination half-life. *Trans R Soc Trop Med Hyg* **87**: 75.
- Weinberg GA (1996). Iron overload as a mechanism for the lowered survival in AIDS patients receiving dapsone-iron protoxylate for secondary prophylaxis of *Pneumocystis carinii* pneumonia. *JID* **174**: 241.
- White C, Franco-Paredes C (2015). Leprosy in the 21st century. *Clin Microbiol Rev* **28**: 80.
- WHO (World Health Organization) (1994). Chemotherapy for leprosy. Technical report series No. 847. Geneva, Switzerland: WHO.
- WHO (World Health Organization) (1982). Chemotherapy of leprosy for control programmes. Technical report series No. 675. Geneva, Switzerland: WHO.
- WHO (World Health Organization) (2008). Dacart development terminated and LapDap recalled. *WHO Drug Information* **22**: 11.
- WHO (World Health Organization) (2013). Global leprosy: update on the 2012 situation. *Weekly Epidemiological Record* **88**: 365.
- WHO (World Health Organization) (2012). WHO Expert Committee on leprosy: eighth report. Technical report series No. 968. Geneva, Switzerland: WHO.
- WHO (World Health Organization) (1977). WHO Expert Committee on Leprosy: fifth report. Technical report series No. 607. Geneva, Switzerland: WHO.
- WHO (World Health Organization) (1998). WHO Expert Committee on Leprosy: seventh report. Technical report series No. 874. Geneva, Switzerland: WHO.
- WHO (World Health Organization) Technical Advisory Group on Leprosy Control (2006). Report of the eighth meeting of the WHO Technical Advisory Group on Leprosy Control. Geneva, Switzerland: WHO.
- WHO (World Health Organization) Technical Consultation (2004). Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated *falciparum* malaria in Africa. Report of a technical consultation convened by WHO. Geneva, Switzerland, July 1-2.
- Wiholm BE, Emanuelsson S (1996). Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. *Eur J Haematol* **60** (Suppl): 42.
- Williams DL, Gillis TP (2004). Molecular detection of resistance in *Mycobacterium leprae*. *Lepr Rev* **75**: 118.
- Williams DL, Pittman T, Gillis TP et al. (2001). Simultaneous detection of *Mycobacterium leprae* and its susceptibility to dapsone using DNA heteroduplex analysis. *J Clin Microbiol* **39**: 2083.
- Williams DL, Spring L, Harris E et al. (2000). Dihydropteroate synthase of *Mycobacterium leprae* and dapsone resistance. *Antimicrob Agents Chemother* **44**: 1530.
- Wilson EJ, Horsley KW, van der Hoek R (2007). *Dapsone Exposure and Australian Vietnam Service: Mortality and Cancer Incidence*. Canberra: Department of Veterans' Affairs. Commonwealth of Australia.
- Winter HR, Wang Y, Unadkat JD (2000). CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. *Drug Metab Dispos* **28**: 865.
- Wolf R, Tuzun B, Tuzun Y (2000). Dapsone: unapproved uses or indications. *Clin Dermatol* **18**: 37.
- Wozel G (1989). The story of sulfones in tropical medicine and dermatology. *Int J Dermatol* **28**: 17.
- Wozel G, Blasum C (2014). Dapsone in dermatology and beyond. *Arch Dermatol Res* **306**: 103.
- Wynia MK, Ioannidis JP, Lau J et al. (1998). Analysis of life-long strategies to prevent *Pneumocystis carinii* pneumonia in patients with variable HIV progression rates. *AIDS* **12**: 1317.
- Yan J, Huang B, Liu G et al. (2013). Meta-analysis of prevention and treatment of toxoplasmic encephalitis in HIV-infected patients. *Acta Trop* **127**: 236.
- Zimmerman HL (1999). Hepatotoxicity. In *Hepatotoxicity* (Zimmerman HJ, ed). Philadelphia: Lippincott Williams and Wilkins.
- Zhang FR, Liu H, Irwanto A et al. (2013). HLA-B*13:01 and the dapsone hypersensitivity syndrome. *N Engl J Med* **369**: 1620.
- Zhu YI, Stiller MJ (2001). Dapsone and sulfones in dermatology: overview and update. *J Am Acad Dermatol* **45**: 420.
- Zuidema J, Hilbers-Modderman E, Merkus F (1986). Clinical pharmacokinetics of dapsone. *Clin Pharmacokinet* **11**: 299.